Diagnostic Findings in Chronic Lymphocytic Leukaemia (CLL): Peripheral Blood Smear, Bone Marrow Aspiration, Iron Storage, and Immunophenotype
Creators
- 1. Assistant Professor, Department of Pathology, Swaminarayan Institute of Medical Sciences & Research, Kalol, Gandhinagar
Description
Background: One of the most prevalent forms of adult leukemia is chronic lymphocytic leukemia (CLL), which can proceed in a variety of ways and present with a wide range of signs and symptoms. In this study, we looked into the correlation and frequency of laboratory results for CLL patients, such as cellular Immunophenotyping, bone marrow aspiration and biopsy, and peripheral blood smear. Methods: All 161 patients with a confirmed diagnosis of CLL had their laboratory data retrieved for this cross-sectional, retrospective analysis. Descriptive statistics were used to assess the frequency and correlation between various laboratory parameters. Techniques with the Jamovi software update (2022). Results: 161 individuals had their laboratory and demographic characteristics, including thrombocytopenia, anaemia, white blood cell count, lymphocyte percentage, and patterns of bone marrow involvement, assessed. There was a substantial correlation between the percentage of atypical lymphocytes in peripheral blood and the percentage of FMC7 marker expression in the bone marrow. Conclusion: A variety of diagnostic methods can be used to identify chronic lymphocytic leukaemia, a common kind of leukaemia linked to significant death and morbidity. Examining the frequency of certain diagnostic tests and analysing their findings these symptoms in those who have the illness can be very helpful for an early diagnosis and prognosis assessment in those who are affected.
Abstract (English)
Background: One of the most prevalent forms of adult leukemia is chronic lymphocytic leukemia (CLL), which can proceed in a variety of ways and present with a wide range of signs and symptoms. In this study, we looked into the correlation and frequency of laboratory results for CLL patients, such as cellular Immunophenotyping, bone marrow aspiration and biopsy, and peripheral blood smear. Methods: All 161 patients with a confirmed diagnosis of CLL had their laboratory data retrieved for this cross-sectional, retrospective analysis. Descriptive statistics were used to assess the frequency and correlation between various laboratory parameters. Techniques with the Jamovi software update (2022). Results: 161 individuals had their laboratory and demographic characteristics, including thrombocytopenia, anaemia, white blood cell count, lymphocyte percentage, and patterns of bone marrow involvement, assessed. There was a substantial correlation between the percentage of atypical lymphocytes in peripheral blood and the percentage of FMC7 marker expression in the bone marrow. Conclusion: A variety of diagnostic methods can be used to identify chronic lymphocytic leukaemia, a common kind of leukaemia linked to significant death and morbidity. Examining the frequency of certain diagnostic tests and analysing their findings these symptoms in those who have the illness can be very helpful for an early diagnosis and prognosis assessment in those who are affected.
Files
IJPCR,Vol16,Issue7,Article220.pdf
Files
(1.5 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:8b467fef6d0d51c8b417333b3cba999b
|
1.5 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-06-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue7,Article220.pdf
- Development Status
- Active
References
- 1. Vosoughi T, Bagheri M, Hosseinzadeh M, Ehsanpour A, Davari N, Saki N. CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. J Cell Physiol. 2019; 234(11):19420-39. [DOI:10.1002/jcp.28 724] [PMID] 2. Kellner J, Wierda W, Shpall E, Keating M, McNiece I. Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leukemia Res. 2016; 40:54-9. [DOI:10.1016/j.leukres. 2015.10.008] [PMID] 3. Hallek M, Cheson BD, Catovsky D, CaligarisCappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood J Am Soc Hematol. 2008; 111(12):5446-56. [DOI:10.1182/blood-2007-06-093906] [PMID] 4. Hallek M, Al‐Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021; 96(12):1679-705. [DOI:10.1002/ajh.26367] [PMID] 5. Panovská A, Doubek M, Brychtová Y, Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk. 2010; 10(4): 297-300. [DOI:10.3816/CL ML.2010.n.061] [PMID] 6. Koohi F, Salehiniya H, Shamlou R, Eslami S, Ghojogh ZM, Kor Y, Rafiemanesh H. Leukemia in Iran: Epidemiology and Morphology Trends. Asian Pac J Cancer Prev. 2015; 16(17):7759-63. [DOI:10.7314/APJCP. 2015.16.17.7759] [PMID] 7. Hojjat Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Shamsian Khoramabadi A, Rabbani H, Shokri F. Immunophenotypic characterization of th leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression. Iran J Immunol. 2008; 5(1):25-35. 8. Allahmoradi E, Taghiloo S, Janbabaei G, Shekarriz R, Tehrani M, Asgarian-Omran H. Immunophenotypic Characterization of Patients with Chronic Lymphocytic Leukemia by Flow Cytometry; Association with Disease Prognosis. J Mazandaran Univ Med Sci. 2017; 26(145):9- 19. 9. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(11):1844. [DOI:10.12 00/JCO.2008.17.0795] [PMID] 10. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018; 391(10129):1524-37. [DOI: 10.1016/S0140-67 36(18)30422-7] [PMID] 11. Naeim F, Rao PN, Grody WW. Hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches. 2009. 12. Rai KR, Wasil T, Iqbal U, Driscoll N, Patel D, Janson D, Mehrotra B. Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin. 2004; 18(4):795-805. [DOI:10.1016/j.hoc.2004.04.00 1] [PMID] 13. Strati P, Jain N, O'Brien S, editors. Chronic lymphocytic leukemia: diagnosis and treat-ment. Mayo Clinic Proceedings; 2018: Elsevier. [DOI:10.1016/j.mayocp.2018.03.002] [PMID] 14. Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic Lymphocytic Leukemia. 2017. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36(7): 1720-48. [DOI: 10.1038/s41375-022-01620-2] [PMID] 15. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods E-book: Elsevier Health Sciences; 2021. 16. Robak T, Krawczyńska A, Cebula-Obrzut B, Urbaniak M, Iskierka-Jażdżewska E, Robak P. Atypical Chronic Lymphocytic Leukemia-The Current Status. Cancers. 2023; 15(18):4427. [DOI:10.3390/cancers15184427] [PMID] 17. Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol. 2016; 174(5):767-75. [DOI:10.11 11/bjh.14132] [PMID] 18. Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. American family physician. 2014; 89(9):731-8. 19. Inamdar KV, Bueso-Ramos CE. Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol. 2007; 11(5):363-89. [DOI:10.1016/j.anndiagpath.2007.08.002] [PMID] 20. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000; 4(1):22-47.[DOI:10.1046/j.1468-0734.2000.0 0002.x] [PMID] 21. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early- stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859-69. [DOI:10.1182/blood.2019003453] [PMID] 22. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018; 94(1):121-8. [DOI:10.1002/cyto.b.21595] [PMID] 23. Rosai J. Rosai and Ackerman's Surgical Pathology E- Book: Elsevier Health Sciences; 2011. 24. Naeim F. Atlas of hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches: Academic press; 2012. 25. Bagheri M, Vosoughi T, Hosseinzadeh M, Saki N. Evaluation of immunophenotypic markers and clinico- hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes. 2020; 13:1-6. [DOI: 10.1186/s13104-020-05243-7] [PMID] 26. Basabaeen AA, Abdelgader EA, Babekir EA, Abdelateif NM, Abdelrahim SO, Altayeb OA, et al. Characteristics of Chronic Lymphocytic Leukemia in Sudanese Patients. Asian Pac J Cancer Care. 2022; 7(3):467-74. [DOI:10.31 557/apjcc.2022.7.3.467-474] 27. Payandeh M, Sadeghi E, Sadeghi M. Survival and clinical aspects for patients with chronic lymphocytic leukemia in Kermanshah, Iran. Asian Pac J Cancer Prev. 2015; 16(17):79 87-90.[DOI:10.7314/APJCP.2015. 16.17.7987] [PMID]